H1 and Novo Nordisk team up to put AI at the centre of clinical trials

Eighty-five percent of the top 20 pharmaceutical companies already rely on H1. Now the New York-based AI platform has secured one of its most significant partnerships to date, joining forces with Danish pharmaceutical giant Novo Nordisk to accelerate clinical development using AI-powered data and workflows.

The agreement, announced on 4 August 2026, goes beyond a standard technology licensing deal. As part of the arrangement, H1 will acquire rights to StudyHub, a digital and AI-enabled platform for clinical development that Novo Nordisk built internally. H1 will take that platform forward, integrating it with its own proprietary data infrastructure and agentic AI capabilities.

Ariel Katz, CEO of H1, was direct about the ambition: "The way clinical trials should be executed needs to change." That is not rhetoric. Clinical trials remain one of the most expensive and time-consuming stages in drug development, and inefficiencies in site selection, patient enrollment, and study design cost the industry billions each year. Reducing those cycle times, even marginally, has a material impact on when drugs reach patients.

How will it work?

At the core of H1's platform is what the company calls its Doctor Graph, a structured data model that maps physician identity, expertise, relationships, and behavioural signals across the global healthcare system. For clinical trials, this matters because identifying the right investigators and sites is one of the most consequential decisions a sponsor makes early in development.

Under the partnership, Novo Nordisk will use H1's capabilities across three specific areas:

• Clinical trial design, using AI-ready data to model study parameters more precisely before trials begin
• Site selection, drawing on the Doctor Graph to match investigator expertise and patient population access to specific trial requirements
• Enrollment optimisation, improving the speed and quality of patient recruitment across active studies

Mishal Patel, Group Vice President of AI and Digital Innovation in R&D at Novo Nordisk, said the company chose H1 because of its "domain expertise, AI-ready proprietary data, and AI technology." That combination, he added, would help reduce cycle times and address process inefficiencies at scale.

Why does it matter?

For the pharmaceutical sector, this partnership reflects a shift that has been building for several years. AI adoption in clinical operations has moved from experimental pilots to strategic infrastructure. But the difference here is the depth of integration. Acquiring StudyHub means H1 is not just providing a data layer on top of existing processes. It is taking ownership of a purpose-built clinical development platform and expanding it.

For the GCC, where Saudi Arabia's Vision 2030 and the UAE's national health strategy both place significant emphasis on becoming regional hubs for clinical research and life sciences investment, this kind of development is directly relevant. Partnerships that compress the drug development timeline also make international sponsors more likely to consider Gulf sites for trial participation, particularly where patient populations with specific disease profiles, including type 2 diabetes and obesity, are clinically significant.

The context

Novo Nordisk has been under considerable commercial pressure to manage its pipeline efficiently. The global demand for GLP-1 therapies has stretched manufacturing and accelerated the need for faster development cycles across its broader portfolio. Investing in AI-driven trial infrastructure is a logical response to that pressure.

H1, for its part, is expanding its role from a physician engagement tool into a full clinical development platform. That is a meaningful strategic step. And with StudyHub now under its control, the company has both the asset and the partnership to make that positioning credible.